Assorted News from the Last Week: The National Comprehensive Cancer Network® (NCCN®) published its first ever set of treatment recommendations pertaining to neuroblastoma. Replacing brentuximab
Assorted News from the Last Week: Hispanic population appears underrepresented in pediatric cancer trials. Liquid biopsies to monitor therapy success and to predict the recurrence
Assorted News from the Last Week: A year after an investigation revealed widespread use of a substandard version of asparaginase, the World Health Organization and
Assorted News from the Last Week: The Coalition Against Childhood Cancer (CAC2) takes great pride in introducing its groundbreaking CAC2 Survivorship Toolkit. Training that increases
Assorted News from the Last Week: The Coalition Against Childhood Cancer (CAC2) takes great pride in introducing its groundbreaking CAC2 Survivorship Toolkit. Scientists found that
Welcome to 2024 and the 201st edition of the CAC2 Childhood Cancer Community News Digest! Assorted News from the Last Week: The FDA granted a
For many, the holiday season is a time of joy, togetherness, and reflection. However, families dealing with the harsh reality of pediatric cancers face exceptional
Assorted News from the Last Week: CAC2 Members Nicole Scobie (Zoe4Life) and Nick Bird (Solving Kids’ Cancer-UK) contributed to this Journal of Clinical Oncology commentary
Assorted News from the Last Week: Dr. Andy Kolb of CAC2 Member Leukemia & Lymphoma Society explains why a well-meaning FDA policy is a threat
Assorted News from the Last Week: World Health Organization (WHO) Foundation report on global childhood cancer A collaboration of researchers has published successful results from
